Adaptive Biotechnologies Corp(ADPT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,063 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ADPT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Adaptive Biotechnologies Corp (ADPT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ADPT at 41.4/100 on a 32-signal composite quality model, placing it at rank #2,063 of 2,962 stocks — the bottom half of the AI-ranked universe. ADPT scores in the top quartile across revenue growth (89.3), institutional flow (80.7). Areas of concern include balance sheet strength (16.2) and profitability (17.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Adaptive Biotechnologies Corp reports quarterly revenue of $71.6M, net income of $-39.8M, an operating margin of -22.0%. Top institutional holders of ADPT by reported 13-F value include VIKING GLOBAL INVESTORS, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ADPT trades on the Nasdaq exchange and files with the SEC under CIK 1478320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Adaptive Biotechnologies Corp directly from SEC EDGAR. Adaptive Biotechnologies Corp's 13F Pro composite quality score has ranged between 19 and 41 since 2021, currently 41.4 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$71.6M
Net Income
Q2 2026
$-39.8M
Free Cash Flow
Q2 2026
$-7.6M
Operating Margin
Q2 2026
-22.0%
ROIC
Q2 2026
-44.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+54.8% YoYNet Income
+62.7% YoYOperating Income
+64.9% YoYEPS (Diluted)
+63.9% YoYTotal Assets
-4.9% YoYTotal Debt
-1.6% YoYOp. Cash Flow
+51.7% YoYFree Cash Flow
+50.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $277.0M +54.8% | $179.0M +5.1% | $170.3M -8.1% | $185.3M +20.1% | $154.3M +56.9% | $98.4M |
| Net Income | $-59.5M +62.7% | $-159.5M +29.2% | $-225.3M -12.5% | $-200.2M +3.4% | $-207.3M -41.8% | $-146.2M |
| Operating Income | $-57.1M +64.9% | $-162.5M +28.4% | $-227.0M -13.4% | $-200.2M +4.2% | $-209.0M -36.7% | $-152.8M |
| EPS (Diluted) | $-0.39 +63.9% | $-1.08 +30.8% | $-1.56 -11.4% | $-1.40 +5.4% | $-1.48 -33.3% | $-1.11 |
| Total Assets | $512.7M -4.9% | $539.4M -18.4% | $661.1M -22.8% | $856.6M -7.2% | $923.3M -17.3% | $1.12B |
| Total Debt | $131.2M -1.6% | $133.3M +2.0% | $130.7M +4.2% | $125.4M | — | — |
| Operating Cash Flow | $-46.0M +51.7% | $-95.2M +39.1% | $-156.3M +15.0% | $-183.9M +4.6% | $-192.7M -28.8% | $-149.7M |
| Free Cash Flow | $-48.9M +50.5% | $-98.9M +40.8% | $-167.0M +16.6% | $-200.3M +21.3% | $-254.5M -51.0% | $-168.5M |
Get alerted when ADPT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Adaptive Biotechnologies Corp including:
Top Institutional Holders of ADPT
VIKING GLOBAL INVESTORS LP
$643.4M29,993,708 shBlackRock, Inc.
$324.7M15,139,159 shVANGUARD CAPITAL MANAGEMENT LLC
$137.4M6,403,587 shWELLINGTON MANAGEMENT GROUP LLP
$126.8M5,911,366 shVANGUARD PORTFOLIO MANAGEMENT LLC
$117.5M5,476,231 shD. E. Shaw & Co., Inc.
$99.2M4,625,859 shWESTFIELD CAPITAL MANAGEMENT CO LP
$91.5M4,267,645 shGEODE CAPITAL MANAGEMENT, LLC
$78.1M3,641,837 shSTATE STREET CORP
$74.2M3,458,388 shInvesco Ltd.
$66.4M3,094,011 sh
| Fund | Value | Shares |
|---|---|---|
| VIKING GLOBAL INVESTORS LP | $643.4M | 29,993,708 |
| BlackRock, Inc. | $324.7M | 15,139,159 |
| VANGUARD CAPITAL MANAGEMENT LLC | $137.4M | 6,403,587 |
| WELLINGTON MANAGEMENT GROUP LLP | $126.8M | 5,911,366 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $117.5M | 5,476,231 |
| D. E. Shaw & Co., Inc. | $99.2M | 4,625,859 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $91.5M | 4,267,645 |
| GEODE CAPITAL MANAGEMENT, LLC | $78.1M | 3,641,837 |
| STATE STREET CORP | $74.2M | 3,458,388 |
| Invesco Ltd. | $66.4M | 3,094,011 |
Companies Similar to ADPT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Guardant Health, Inc.
Axogen, Inc.
GLAUKOS Corp
Twist Bioscience Corp
Axsome Therapeutics, Inc.
RHYTHM PHARMACEUTICALS, INC.
Mirum Pharmaceuticals, Inc.
ARROWHEAD PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ADPT on your watchlist
Track score changes the day Adaptive Biotechnologies Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ADPT a good stock to buy?
13F Pro's AI-powered analysis of Adaptive Biotechnologies Corp (ADPT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ADPT are available on the ADPT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ADPT is classified as a mid company.
Which hedge funds own ADPT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ADPT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Adaptive Biotechnologies Corp's investment landscape.